Patrick W. Smith Sells 47,314 Shares of Axon Enterprise, Inc. (NASDAQ:AXON) Stock

Axon Enterprise, Inc. (NASDAQ:AXON) CEO Patrick W. Smith sold 47,314 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $400.07, for a total value of $18,928,911.98. Following the completion of the sale, the chief executive officer now directly owns 2,983,802 shares of the company’s stock, valued at approximately $1,193,729,666.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $415.05 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. Axon Enterprise, Inc. has a 12 month low of $190.01 and a 12 month high of $415.11. The company has a fifty day moving average price of $361.35 and a two-hundred day moving average price of $322.04. The company has a market cap of $31.32 billion, a PE ratio of 121.36, a P/E/G ratio of 10.59 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. The business had revenue of $504.00 million during the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company’s quarterly revenue was up 34.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.80 EPS. Research analysts expect that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Craig Hallum upped their price target on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $400.00 price target on shares of Axon Enterprise in a report on Wednesday, August 7th. Barclays boosted their price objective on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Northland Securities raised their target price on Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Finally, JMP Securities boosted their price target on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $365.38.

Hedge Funds Weigh In On Axon Enterprise

Several institutional investors have recently made changes to their positions in AXON. Avantax Advisory Services Inc. lifted its holdings in shares of Axon Enterprise by 0.8% in the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after purchasing an additional 40 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Axon Enterprise during the first quarter valued at $931,000. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Axon Enterprise by 14.8% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock worth $53,307,000 after acquiring an additional 22,013 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Axon Enterprise by 21.7% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock worth $2,693,000 after acquiring an additional 1,634 shares during the period. Finally, Cim LLC acquired a new stake in shares of Axon Enterprise in the 4th quarter worth about $1,409,000. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.